First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation
First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First […]
First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First […]
Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc.,
Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve
Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences,
Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar
Frank Tagliaferri, Ph.D., Vice President of Pharmaceutical Development sat down with BioProcess International to discuss the growth the industry, and
Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The
Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use
Acquisition allows Pace to support a growing number of clients requiring services throughout the drug development process while adding expertise
The installation and validation of our LabVantage Laboratory Information Management System (LIMS) is complete in our Philadelphia site! Staff